1
|
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D’Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. JAMA Dermatol 2024; 160:290-296. [PMID: 38265821 PMCID: PMC10809134 DOI: 10.1001/jamadermatol.2023.5679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/03/2023] [Indexed: 01/25/2024]
Abstract
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. Objective To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. Design, Setting, and Participants This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015. Exposure Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group. Main outcomes and measures The primary outcome was the 5- and 7-year disease-free survival (DFS) without corticosteroids, assessed by Kaplan-Meier curves. Secondary outcomes were occurrence of relapse, occurrence of severe adverse events (SAEs), and evolution of antidesmoglein (Dsg) antibody enzyme-linked immunosorbent assay values to predict long-term relapse. Results Of the 90 patients in the Ritux 3 trial, 83 were evaluated at the end of follow-up study visit (44 in the rituximab plus prednisone group; 39 in the prednisone-alone group) with a median (IQR) follow-up of 87.3 (79.1-97.5) months. Forty-three patients (93%) from the rituximab plus prednisone and 17 patients (39%) from the prednisone-alone group had achieved complete remission without corticosteroids at any time during the follow-up. Patients from the rituximab group had much longer 5- and 7-year DFS without corticosteroids than patients from the prednisone-alone group (76.7% and 72.1% vs 35.3% and 35.3%, respectively; P < .001), and had about half the relapses (42.2% vs 83.7%; P < .001). Patients who received rituximab as second-line treatment had shorter DFS than patients treated as first line (P = .007). Fewer SAEs were reported in the rituximab plus prednisone group compared with the prednisone-alone group, 31 vs 58 respectively, corresponding to 0.67 and 1.32 SAEs per patient, respectively (P = .003). The combination of anti-Dsg1 values of 20 or more IU/mL and/or anti-Dsg3 values of 48 or more IU/mL yielded 0.83 positive predictive value and 0.94 negative predictive value to predict long-term relapse. Conclusions and Relevance In this secondary analysis of the Ritux 3 trail, first-line treatment of patients with pemphigus with the Ritux 3 regimen was associated with long-term sustained complete remission without corticosteroid therapy without any additional maintenance infusion of rituximab.
Collapse
Affiliation(s)
- Billal Tedbirt
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Maud Maho-Vaillant
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Estelle Houivet
- Department of Biostatistics and Clinical Research, CHU Rouen, Rouen, France
| | - Claire Mignard
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Marie-Laure Golinski
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Sébastien Calbo
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Catherine Prost-Squarcioni
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint-Étienne, Saint-Étienne, France
| | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Marie-Aleth Richard
- CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitaire Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, 13385, Marseille, France
| | | | | | | | | | - Frédéric Caux
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Marina Alexandre
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Philippe Musette
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Gaëlle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sébastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | | | - Michel D’Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, APHP and University of Paris cité, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Jacques Benichou
- Department of Biostatistics and Clinical Research, CHU Rouen and Inserm U1018, Université Paris-Saclay and Université de Rouen, Rouen, France
| | - Pascal Joly
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Vivien Hébert
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
2
|
Lauron S, Plasse C, Vaysset M, Pereira B, D’Incan M, Rondepierre F, Jalenques I. Prevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatol 2023; 159:281-288. [PMID: 36696123 PMCID: PMC9878435 DOI: 10.1001/jamadermatol.2022.6085] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 11/23/2022] [Indexed: 01/26/2023]
Abstract
Importance Two recent meta-analyses reported a high prevalence of both anxiety and depression in patients with alopecia areata (AA), as well as a positive association of AA with anxiety and depression, without distinguishing between disorders and symptoms. Yet, depression and anxiety can manifest either as symptoms identified in questionnaires or as specific diagnoses defined by Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision criteria. Objective To perform a large meta-analysis separating the prevalence of depressive and anxiety disorders from that of depressive and anxiety symptoms in patients with AA. Data Sources PubMed, ScienceDirect, the Cochrane Library, Embase, and PsycINFO databases were searched from inception through August 1, 2020. Study Selection Studies that contained data on the prevalence of depressive or anxiety disorders or symptoms were included. Data Extraction and Synthesis The Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines were used. Pooled prevalence was calculated with a random effects model meta-analysis that took into account between- and within-study variability. Meta-regressions were used to study the association between variations in prevalence and study characteristics. Main Outcomes and Measures The prevalence of depressive and anxiety disorders and symptoms in patients with AA. Results Thirty-seven articles (29 on depression and 26 on anxiety) that met the inclusion criteria were identified. By distinguishing between disorders and symptoms, the prevalence of both depressive disorders (9%) and unspecified anxiety disorders (13%) in patients with AA was shown to be greater than that in the general population. The prevalence and odds ratio (OR) of depressive disorders (prevalence, 9%; OR, 1.38) and anxiety disorders of which each category had been specifically studied (prevalence, 7%-17%; OR, 1.51-1.69) were markedly lower than that of depressive symptoms (prevalence, 37%; OR, 2.70) and anxiety symptoms (prevalence, 34%; OR, 3.07). Meta-regressions showed that variations in prevalence were mainly associated with methodological differences between studies. Conclusions and Relevance In this systematic review and meta-analysis, the separate analyses showed that 7% to 17% of patients with AA had depressive or anxiety disorders that require psychiatric care, including specific medication. Additionally, more than one-third of patients had symptoms that are warning signs and that need monitoring because they can develop into disorders.
Collapse
Affiliation(s)
- Sophie Lauron
- Pascal Institut, Adult Psychiatry and Medical Psychology Department, CNRS, CHU Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Camille Plasse
- Pascal Institut, Adult Psychiatry and Medical Psychology Department, CNRS, CHU Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Marion Vaysset
- Pascal Institut, Adult Psychiatry and Medical Psychology Department, CNRS, CHU Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| | - Bruno Pereira
- Department of Clinical Research and Innovation, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Michel D’Incan
- Dermatology Department, Clermont Auvergne University, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Fabien Rondepierre
- Adult Psychiatry and Medical Psychology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Isabelle Jalenques
- Clermont Auvergne INP, Pascal Institut, Adult Psychiatry and Medical Psychology Department, CNRS, CHU Clermont-Ferrand, Clermont Auvergne University, Clermont-Ferrand, France
| |
Collapse
|
3
|
Rondepierre F, Tauveron-Jalenques U, Valette S, Mulliez A, D’Incan M, Lauron S, Jalenques I. Psychiatric symptomatology in skin-restricted lupus patients without axis I psychiatric disorders: A post-hoc analysis. PLoS One 2023; 18:e0282079. [PMID: 36857334 PMCID: PMC9977055 DOI: 10.1371/journal.pone.0282079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 02/07/2023] [Indexed: 03/02/2023] Open
Abstract
BACKGROUND Skin-restricted lupus is a chronic inflammatory disease associated with high rates of depression and anxiety disorders. Patients without psychiatric disorders can experience anxiety and depressive symptoms at a subclinical level, which could be risk factors for progression towards psychiatric disorders. It was decided, therefore, to investigate the presence of specific symptoms in skin-restricted lupus patients without axis I psychiatric disorders and their impact on the occurrence of axis I psychiatric disorders during the study follow-up. METHODS Longitudinal data of 38 patients and 76 matched controls without active axis I psychiatric disorders from the LuPsy cohort were used. Depressive, neurovegetative, psychic and somatic anxiety symptom scores were established from the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating scale (HAMA). RESULTS None of the participants had any current active axis I psychiatric disorders but the patients had personality disorders more frequently and had received more past psychotropic treatments than the controls. They also had higher MADRS and HAMA scores than the controls, in particular neurovegetative, psychic anxiety and somatic symptoms scores. No dermatological factor tested was associated with these scores, whereas being a lupus patient was associated with higher neurovegetative and somatic symptoms scores, having a current personality disorder with higher depressive and neurovegetative scores and receiving more past psychotropic treatments with psychic anxiety and somatic symptoms scores. The occurrence of psychiatric disorders during the study follow-up was associated with an elevated psychic anxiety score at baseline and past psychotropic treatment but not with history of psychiatric disorder. LIMITATIONS The LuPsy cohort included a large number of patients with axis I psychiatric disorders, the sample without axis I psychiatric disorders is therefore limited. CONCLUSIONS We observed numerous psychiatric symptoms among the skin-restricted lupus patients. They should therefore receive special attention in the management of their subclinical symptoms before they progress towards full psychiatric disorders.
Collapse
Affiliation(s)
- Fabien Rondepierre
- CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, Clermont-Ferrand, France
| | - Urbain Tauveron-Jalenques
- Clermont Auvergne Université, CNRS, CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France
| | - Solène Valette
- Clermont Auvergne Université, CNRS, CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France
| | - Aurélien Mulliez
- CHU Clermont-Ferrand, Direction de la Recherche Clinique et de l’Innovation, Clermont-Ferrand, France
| | - Michel D’Incan
- Clermont Auvergne Université, INSERM, CHU Clermont-Ferrand, Service de Dermatologie, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France
| | - Sophie Lauron
- Clermont Auvergne Université, CNRS, CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France
| | - Isabelle Jalenques
- Clermont Auvergne Université, CNRS, CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France,* E-mail:
| |
Collapse
|
4
|
Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D’Incan M, Durando X, Cachin F. Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer 2022; 22:417. [PMID: 35428211 PMCID: PMC9013026 DOI: 10.1186/s12885-022-09495-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 04/06/2022] [Indexed: 11/12/2022] Open
Abstract
Background Benzamide-based radioligands targeting melanin were first developed for imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy (TRT). [131I]ICF01012 presents a highly favorable pharmacokinetics profile in vivo for therapy. Tumour growth reduction and increase survival have been established in preclinical models of melanoma. According the these preclinical results, we initiate a first-in-human study aimed to determine the recommended dose of [131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma. Methods The MELRIV-1 trial is an open-label, multicentric, dose-escalation phase I trial. The study is divided in 2 steps, a selection part with an IV injection of low activity of [131I]ICF01012 (185 MBq at D0) to select patients who might benefit from [131I]ICF01012 TRT in therapeutic part, i.e. patient presenting at least one tumour lesion with [131I]ICF01012 uptake and an acceptable personalized dosimetry to critical organs (liver, kidney, lung and retina). According to dose escalation scheme driven by a Continual Reassessment Method (CRM) design, a single therapeutic injection of 800 MBq/m2, or 1600 MBq/m2, or 2700 MBq/m2 or 4000 MBq/m2 of [131I]ICF01012 will be administered at D11 (± 4 days). The primary endpoint is the recommended therapeutic dose of [131I]ICF01012, with DLT defined as any grade 3-4 NCI-CT toxicity during the 6 weeks following therapeutic dose. Safety, pharmacokinetic, biodistribution (using planar whole body and SPECT-CT acquisitions), sensitivity / specificity of [131I]ICF01012, and therapeutic efficacy will be assessed as secondary objectives. Patients who received therapeutic injection will be followed until 3 months after TRT. Since 6 to 18 patients are needed for the therapeutic part, up to 36 patients will be enrolled in the selection part. Discussion This study is a first-in-human trial evaluating the [131I]ICF01012 TRT in metastatic malignant melanomas with a diagnostic dose of the [131I]ICF01012 to select the patients who may benefit from a therapeutic dose of [131I]ICF01012, with at least one tumor lesion with [131I]ICF01012 uptake and an acceptable AD to healthy organ. Trial registration Clinicaltrials.gov: NCT03784625. Registered on December 24, 2018. Identifier in French National Agency for the Safety of Medicines and Health Products (ANSM): N°EudraCT 2016-002444-17.
Collapse
|
5
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D’Incan M, Grange F, Braniste V, Bagot M. French real-life retrospective study in patients with mycosis fungoides and Sezary syndrome treated by mogamulizumab. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00738-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Akil H, Quintana M, Raymond JH, Billoux T, Benboubker V, Besse S, Auzeloux P, Delmas V, Petit V, Larue L, D’Incan M, Degoul F, Rouanet J. Efficacy of Targeted Radionuclide Therapy Using [ 131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers (Basel) 2021; 13:cancers13061421. [PMID: 33804655 PMCID: PMC8003594 DOI: 10.3390/cancers13061421] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Revised: 03/12/2021] [Accepted: 03/16/2021] [Indexed: 12/13/2022] Open
Abstract
Simple Summary Targeted radionuclide therapy (TRT) aims to selectively deliver radioactive molecules to tumor cells. For this purpose, we deliver iodine-131 ([131I]) to melanoma cells by using our laboratory-developed melanin specific radiotracer, the ICF01012. Approximately 50% and 20%–30% of human melanomas have activating mutation in BRAF or NRAS genes, respectively. These mutations lead to a constitutive activation of the MAPK/ERK pathway, which is known to be involved in tumor cells’ radioresistance. In this work, we showed using 3D in vitro tumor models, an additive efficiency of combining [131I]ICF01012-TRT and MAPK/ERK inhibitors in BRAF- and NRAS-mutant melanoma cells. In mice bearing NRASQ61K-mutated melanoma, TRT induced an impressive decrease in tumor growth, as well as a highly extended survival. Additionally, we showed that TRT reduces the metastatic capacity of melanoma, especially through lymph-node dissemination. These results are therefore of great interest, especially for patients with NRAS-mutant metastatic melanoma who currently lack specific efficient therapies. Abstract Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), in melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently in phase 1 clinical trial (NCT03784625). TRT alone or combined with MEKi was evaluated in three-dimensional melanoma spheroid models of human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. TRT in vivo biodistribution, dosimetry, efficiency, and molecular mechanisms were studied using the C57BL/6J-NRASQ61K 1007 syngeneic model. Results: TRT cooperated with MEKi to increase apoptosis in both BRAF- and NRAS-mutant spheroids. NRASQ61K spheroids were highly radiosensitive towards [131I]ICF01012-TRT. In mice bearing NRASQ61K 1007 melanoma, [131I]ICF01012 induced a significant extended survival (92 vs. 44 days, p < 0.0001), associated with a 93-Gy tumor deposit, and reduced lymph-node metastases. Comparative transcriptomic analyses confirmed a decrease in mitosis, proliferation, and metastasis signatures in TRT-treated vs. control tumors and suggest that TRT acts through an increase in oxidation and inflammation and P53 activation. Conclusion: Our data suggest that [131I]ICF01012-TRT and MEKi combination could be of benefit for advanced pigmented BRAF-mutant melanoma care and that [131I]ICF01012 alone could constitute a new potential NRAS-mutant melanoma treatment.
Collapse
Affiliation(s)
- Hussein Akil
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- CNRS 7276, INSERM U1262, 2 rue du Pr Descottes, 87025 Limoges, France
| | - Mercedes Quintana
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Jérémy H. Raymond
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Tommy Billoux
- Cirmen, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand, France;
| | - Valentin Benboubker
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Sophie Besse
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Philippe Auzeloux
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Véronique Delmas
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Valérie Petit
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Lionel Larue
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Michel D’Incan
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- Department of Dermatology and Oncodermatology, CHU Estaing, 1 Place Aubrac, 63000 Clermont-Ferrand, France
| | - Françoise Degoul
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- CNRS 6293 INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France
| | - Jacques Rouanet
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- Department of Dermatology and Oncodermatology, CHU Estaing, 1 Place Aubrac, 63000 Clermont-Ferrand, France
- Correspondence:
| |
Collapse
|
7
|
Clement A, Mansard S, Bachelerie M, D’Incan M. Pronostic des lymphomes T cutanés érythrodermiques. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Badrignans M, Oro S, Chong-Si-Tsaon A, Bagny K, Le Masson G, Attencourt C, Legoupil D, Denamps J, Dubois R, Faiz S, Beltzung F, D’Incan M, Koubaa W, Hammami G, Beltraminelli H, Balme B, Dalle S, Dorel M, Nicolae A, Moustaghfir I, Skrek S, Deschamps T, Chaby G, Ortonne N. Le mycosis fongoïde pustuleux, une forme particulièrement agressive : étude clinicopathologique de 36 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Flament J, Jouen F, Tancrède-Bohin E, Oro S, Picard-Dahan C, Konstantinou M, Dereure O, Seta V, Quereux G, Prost C, Bedane C, Debarbieux S, Bourgault-Villada I, Delaporte E, Lacour JP, Richard MA, Pham-Ledard A, D’Incan M, Abasq C, Duvert-Lehembre S, Lombart F, Dupuy A, Hainaut E, Dompmartin A, Leccia MT, Vabres P, Alcaraz I, Michel C, Lagrange B, Litrowski N, Estève E, Machet L, Martin L, Del Giudice P, Fenot M, Belmondo T, Morin F, Tressières B, Joly P, Cordel N. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Sigg N, Delaunay J, Livideanu CB, Aubin F, Bachelez H, Charles J, Dupuy A, Girard C, Goujon-Henry C, D’Incan M, Jullien D, Ly S, Maillard H, Misery L, Montaudié H, Parier J, Perrussel M, Richard MA, Seneschal J, Staumont-Salle D, Viguier M, Bénéton N. Eruptions cutanées dysimmunitaires et inflammatoires au cours d’un traitement par anti IL-17 dans le psoriasis: 47 cas. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D’Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Hervé G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guérin F, Sepulveda F, Bagot M, De Saint-Basile G, Michonneau D, De Masson A. Étude clinique à long terme et mutations HAVCR2 chez 70 patients atteints de lymphome T sous cutané à type de panniculite. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Bastos S, Hebert V, Vassileva S, Patsatsi A, Meijer J, Quéreux G, Bedane C, Prost-Squarcioni C, Debardieux S, Oro S, Chaby G, D’Incan M, Litrowski N, Boulard C, Lunardon L, Kiritsi D, Jedlickova H, Feliciani C, Roussel A, Kottler D, Plantin P, Richard MA, Friedrichsen L, Abasq C, Duvert Lehembre S, Gottlieb J, Zebrowska A, Hofmann S, Joly P. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Pinard C, Duvert-Lehembre S, Prost-Squarcioni C, Alsubaiei F, Houivet E, Le Henaff Y, Heas S, Picard-Dahan C, Bernard P, Doutre M, Beylot-Barry M, Richard MA, Delaporte E, Fleuret C, Oro S, D’Incan M, Alexandre M, Caux F, Maillard H, Bénéton N, Hebert V, Joly P. Évaluation d’un questionnaire de sévérité au cours du pemphigus. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Thévenot J, Ferrier le Bouëdec MC, Buisson A, Bommelaer G, D’Incan M, Rouzaire P. Rapid Desensitization to Adalimumab Is Associated With Decreased Basophil Sensitivity. J Investig Allergol Clin Immunol 2019; 29:141-143. [DOI: 10.18176/jiaci.0350] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019; 139:31-37. [DOI: 10.1016/j.jid.2018.04.042] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 04/20/2018] [Accepted: 04/25/2018] [Indexed: 11/29/2022]
|
17
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Bouaziz J, Ram-Wolff C, Boulinguez S, Dereure O, Bachelez H, Bonnet N, Socie G, Brice P, Brunet-Possenti F, Dalle S, Suarez F, Marçais A, Boccara O, Bodemer C, Adamski H, D’Incan M, Fraitag S, Bagot M, Michonneau D, De Masson A. Lymphomes T sous-cutanés à type de panniculite : étude anatomoclinique rétrospective de 55 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Bouschon P, Waton J, Schmutz JL, D’Incan M, Bouedec MCFL. Eczémas de contact allergiques à la méthylisothiazolinone : évaluation des rechutes après conseils d’éviction auprès de 139 patients. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Rouanet J, Akil H, Viallard C, Bonnet M, Besse S, Witkowski T, Debiton E, Chezal JM, Auzeloux P, Miot-Noirault E, Quintana M, D’Incan M, Degoul F. Radiothérapie interne vectorisée du mélanome : mécanismes moléculaires au sein de sphéroïdes. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Busser B, Sabatier-Vincent M, Trichard F, Pinel N, Bonneterre V, Dugourd P, Coll JL, D’Incan M, Motto-Ros V, Charles J, Sancey L. La spectroscopie laser : une nouvelle aide au diagnostic pathologique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V, D’Incan M, Joly P, Leccia M, Meurant J, Misery L, Petit A, Geffroy BR, Sei J, Taieb C, Ezzedine K. Objectifs peau : une initiative conjointe des dermatologues et de l’industrie au service des patients. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Moulin C, Merlin E, Guesnier-Dopagne M, D’Incan M. Rat bite fever : une dermatose mortelle induite par les NAC. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Reproductibilité inter-observateur des scores de sévérité du pemphigus ABSIS et PDAI. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
26
|
Houivet E, Hebert V, Boulard C, Vaillant M, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni D, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Johannes Steffen Kern J, Hofmann S, Bouyeure A, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz J, Franck N, Vabres P, Labeille B, Aleth Richard M, Delaporte E, Dupuy A, D’Incan M, Quereux G, Skowron F, Paul C, Bulai Livideanu C, Beylot-Barry M, Doutre M, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth V, Murrell D, Hertl M, Benichou J, Joly P. Corrélation entre les scores de sévérité clinique (ABSIS, PDAI, PGA), la qualité de vie (DLQI) et les taux d’Ac anti-desmogléine 1 et 3 dans le suivi du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Skowron F, Bensaid B, Depaepe L, Balme B, Kanitakis J, Amarger S, Maucourt-Boulch D, D’Incan M, Bérard F, Nicolas JF. Analyse de la valeur pronostique des modifications histologiques cutanées lors d’un exanthème induit par les médicaments (forme simple, compliquée et DRESS). Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
28
|
Hurabielle C, Oro S, Merah A, D’Incan M, Joly P, Franck N, Estève E, Maubec E, Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L, Michel C, Quereux G, Saiag P, Ram-Wolff C, Cornillet-Lefebvre P, Lenormand B, Ortonne N, Wechsler J, Bagot M, Delfau-Larue MH. Fréquence et valeur pronostique de la maladie résiduelle dans le mycosis fongoïde. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Viallard C, Chezal JM, Boudhraa Z, Mishellany F, Ranchon-Cole I, Besse S, Miot-Noirault E, D’Incan M, Cachin F, Dutreix M, Degoul F. Traitement du mélanome métastasé par radiothérapie interne vectorisée : mécanismes et potentialisation. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.04.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D’Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M. Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. JAMA Dermatol 2014; 150:535-41. [DOI: 10.1001/jamadermatol.2013.7452] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Florent Grange
- Department of Dermatology, Hôpital Robert Debré, Reims, France
| | - Pascal Joly
- Department of Dermatology, Hôpital Charles Nicolle, Rouen, France
| | - Coralie Barbe
- Unité d’Aide Méthodologique, Hôpital Robert Debré, Reims, France
| | - Martine Bagot
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - Stéphane Dalle
- Department of Dermatology, Hôpital de l’Hôtel-Dieu, Lyon, France
| | | | - Eve Maubec
- Department of Dermatology, Hôpital Bichat, Paris, France
| | - Michel D’Incan
- Department of Dermatology, Hôtel-Dieu, Clermont-Ferrand, France
| | | | - Sophie Dalac
- Department of Dermatology, Hôpital du Bocage, Dijon, France
| | | | - Eric Esteve
- Department of Dermatology, Hôpital Porte Madeleine, Orléans, France
| | - Gaëlle Quereux
- Department of Dermatology, Hôpital de l’Hôtel-Dieu, Nantes, France
| | - Laurent Machet
- Department of Dermatology, Hôpital Trousseau, Tours, France
| | - Marion Leduc
- Department of Clinical Research, Hôpital Maison Blanche, Reims, France
| | - Olivier Dereure
- Department of Dermatology, Hôpital Saint-Eloi, Montpellier, France
| | - Liliane Laroche
- Department of Dermatology, Hôpital Avicenne, Bobigny, France
| | - Philippe Saiag
- Department of Dermatology, Hôpital Ambroise Paré, Boulogne, France
| | - Béatrice Vergier
- Department of Pathology, Hôpital du Haut Lévêque, Pessac, France
| | | |
Collapse
|
31
|
Commin M, Prost C, Picard-Dahan C, Duvert-Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Bouaziz J, Oro SIH, Avenel M, Sassolas B, Alexandre M, Caux F, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabres P, Dereure O, Skowron F, Franck N, Barry MB, Maillard H, Debardieux S, Jullien D, Misery L, Ferranti V, Joly P. Analyse intermédiaire de l’efficacité du rituximab comme traitement de première intention du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Ferrier Le Bouëdec MC, Gaillard A, Cayrol J, Vernet G, D’Incan M. « Dermite des Téphras » : nouvelle maladie à caractère professionnel. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Boulard C, Bouyeure A, Houivet E, Borradori L, Huenefeld C, Schmidt E, Marinovic B, Zambruno G, Feliciani C, Prost C, Picard-Dahan C, Duvert Lehembre S, Labeille B, Paul C, Richard M, Dalac S, Bernard P, Dupuy A, Caux F, Bouaziz J, Oro S, Avenel-Audran M, Misery L, Sassolas B, Alexandre M, D’Incan M, Delaporte E, Bedane C, Quereux G, Machet L, Vabre P, Dereure O, Skowron F, Franck N, Beylot-Barry M, Beneton Benhard N, Debarbieux S, Jullien D, Benichou J, Ferranti V, Murrell D, Hertl M, Joly P. Qualité de vie chez les patients atteints de pemphigus : corrélation avec le type et la sévérité du pemphigus. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Ferrier Le Bouëdec MC, Texier C, Gilard AM, Coupelon S, D’Incan M. Eczémas de contact atypiques ou sévères à l’huile essentielle de cannelle. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Piech C, Ferrier Le Bouedec MC, Hospital V, Amarger S, D’Incan M. Photosensibilisation sous Hexaquine®, Berocca®, Ginkor Fort® : rôle du benzoate de quinine. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Grange F, Joly P, Barbe C, Bagot M, Oro S, Maubec E, D’Incan M, Ram-Wolff C, Templier I, Esteve E, Quereux G, Leduc M, Saiag P, Beylot-Barry M. Lymphome B cutané de type membre inférieur : le pronostic s’est amélioré. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Almugairen N, Hopital V, Duvert Lehembre S, Joly P, D’Incan M. Suivi à long terme de 104 patients atteints de pemphigus. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.09.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Piech C, Joly P, Favre E, Favre J, Plesse J, Biard B, Dubois C, Marchesseau A, Roger H, Fouilloux B, Fournier A, Garcier F, Antoniotti O, Joubert J, Frank F, Gentil-Perret A, Godard W, Soulier K, D’Incan M. Les pemphigoïdes bulleuses suivies en ville et à l’hôpital sont-elles comparables ? Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.09.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Perbet S, Salavert M, Amarger S, Constantin JM, D’Incan M, Bazin JE. Fluoroderma after exposure to sevoflurane. Br J Anaesth 2011; 107:106-7. [DOI: 10.1093/bja/aer180] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Hospital V, Amarger S, Franck F, Ferrier Le Bouëdec MC, Souteyrand P, D’Incan M. Dermite de contact lymphomatoïde par procuration. Ann Dermatol Venereol 2011; 138:315-8. [DOI: 10.1016/j.annder.2011.01.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Revised: 12/05/2010] [Accepted: 01/14/2011] [Indexed: 10/18/2022]
|
41
|
Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, Astudillo L, D’Incan M, Bessis D, Thomas L, Debarbieux S, Ammoury A, Lamant L, Paul C. Caractéristiques cliniques et évolutives du scléromyxœdème : étude rétrospective multicentrique. Ann Dermatol Venereol 2010; 137:782-8. [PMID: 21134580 DOI: 10.1016/j.annder.2010.08.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2010] [Revised: 06/15/2010] [Accepted: 08/25/2010] [Indexed: 10/19/2022]
|
42
|
Beylot-Barry M, Dereure O, Vergier B, Barete S, Laroche L, Machet L, Delfau-Larue MH, D’Incan M, Grange F, Ortonne N, Merlio JP, Bagot M. Prise en charge des lymphomes T cutanés : recommandations du Groupe français d’étude des lymphomes cutanés. Ann Dermatol Venereol 2010; 137:611-21. [DOI: 10.1016/j.annder.2010.06.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2010] [Revised: 04/19/2010] [Accepted: 06/22/2010] [Indexed: 10/19/2022]
|
43
|
Grange F, D’Incan M, Ortonne N, Dalac S, Laroche L, Beylot-Barry M, Delfau-Larue MH, Vergier B, Bagot M. Prise en charge des lymphomes B cutanés : recommandations du Groupe français d’étude des lymphomes cutanés. Ann Dermatol Venereol 2010; 137:523-31. [DOI: 10.1016/j.annder.2010.04.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2010] [Revised: 04/13/2010] [Accepted: 04/28/2010] [Indexed: 10/19/2022]
|
44
|
Deschamps ME, Payet S, Tournadre A, Soubrier M, Souteyrand P, D’Incan M. Efficacité de l’infliximab dans le traitement d’une triade d’occlusion folliculaire. Ann Dermatol Venereol 2010; 137:546-50. [DOI: 10.1016/j.annder.2010.06.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2009] [Accepted: 04/30/2010] [Indexed: 11/28/2022]
|
45
|
Merlin E, Kanold J, Hannani D, Terral D, D’Incan M, Demeocq F. P036 - Utilisation de la photochimiothérapie extracorporelle chez l’enfant. Arch Pediatr 2010. [DOI: 10.1016/s0929-693x(10)70437-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, D’Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2009; 162:74-9. [DOI: 10.1111/j.1365-2133.2009.09373.x] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Cachin F, Chezal JM, Miot-Noirault E, Moins N, Auzeloux P, Vidal A, Bonnet-Duquennoy M, Boisgard S, Filaire M, Mestas D, Kelly A, Merlin C, Redini F, D’Incan M, Madelmont JC, Veyre A, Maublant J. Nouveaux traceurs TEMP : exemple des traceurs des protéoglycanes et de la mélanine. Médecine Nucléaire 2009. [DOI: 10.1016/j.mednuc.2009.01.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S, Delaporte E, Dereure O, Bachelez H, Vergier B, Petrella T, D’Incan M. Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab. ACTA ACUST UNITED AC 2009; 145:329-30. [DOI: 10.1001/archdermatol.2009.23] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
49
|
Bocquier B, D’Incan M, Joubert J, Kanitakis J, Salavert M, Tournilhac O, Maitre F, Déchelotte P, Souteyrand P, Estève E, Martin L. Amyloid elastosis: a new case studied extensively by electron microscopy and immunohistochemistry. Br J Dermatol 2008; 158:858-60. [DOI: 10.1111/j.1365-2133.2007.08428.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Salavert M, Amarger S, Bens G, Souteyrand P, D’Incan M. Syndrome polymalformatif associant craniosténose, acanthosis nigricans, dermatite atopique et infections à répétition. Ann Dermatol Venereol 2007. [DOI: 10.1016/s0151-9638(07)89314-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|